ENDO: Continuing Semaglutide Aids Weight Loss in Overweight, Obese
Maintaining treatment resulted in continued weight loss during additional 48 weeks compared with switching to placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.